Epilepsy News and Research

Latest Epilepsy News and Research

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Study reveals how default-mode network neurones interfere with our ability to pay attention

A study carried out by a team at the Centre de Recherche en Neurosciences de Lyon has just revealed how this network interferes with our ability to pay attention, by assessing the activity of the human brain's default-mode network neurones on a millisecond scale for the first time ever, in collaboration with Philippe Kahane's epilepsy department in Grenoble.

4 Nov 2011

TPI announces formulation expansion program for GMOL

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid.

4 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

USC Professor receives NSF's new Innovation Corps award

Last month, for the first time in 11 years, USC Associate Professor Ellis Meng found herself raising her hand and asking questions in the classroom - not answering them.

3 Nov 2011

Study supports existence of metastable frequency-band-dependent scaffold of brain connectivity

Over the past two decades, the increased ability to analyze relationships among neural structures has provided novel insights into brain function. Most network approaches, how-ever, focus on static representations of the brain's physical or statistical connectivity.

2 Nov 2011

FDA approves expansion of MRI use with Cyberonics' VNS Therapy System

Cyberonics, Inc., a global leader in medical devices for the treatment and management of epilepsy, today announced that the U.S. Food and Drug Administration approved a significant expansion of options for Magnetic Resonance Imaging use by patients who have the VNS Therapy System.

1 Nov 2011

AAN names 30 neurologists to attend Palatucci Advocacy Leadership Forum

The American Academy of Neurology has named 30 neurologists from around the world to attend the esteemed Donald M. Palatucci Advocacy Leadership Forum, January 12-15, 2012, in Austin, Texas.

1 Nov 2011

Researchers discover biomarker for earlier diagnosis of MS

Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called "blurring", may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, such as multiple sclerosis.

1 Nov 2011

Dementia people with stroke more likely to become disabled and not return home

New research shows people with dementia who have a stroke are more likely to become disabled and not return home compared to people who didn't have dementia at the time they had a stroke.

1 Nov 2011

Researchers identify FMRP protein as key player in RNA editing

The most common form of heritable cognitive impairment is Fragile X Syndrome, caused by mutation or malfunction of the FMR1 gene. Loss of FMR1 function is also the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others.

31 Oct 2011

Special hospital team reduces cumulated risk of stroke in TIA patients

Patients who had a transient ischaemic attack (TIA), sometimes referred to as a "mini stroke", were much less likely to experience further vascular events in the first year if their care was co-ordinated by a special hospital team.

28 Oct 2011

Fasudil drug shows promise against cerebral cavernous malformation

A drug treatment has been proven to prevent lesions from cerebral cavernous malformation — a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke — for the first time in a new study.

28 Oct 2011

external Trigeminal Nerve Stimulation pediatric clinical trial for ADHD receives NeuroSigma funding

NeuroSigma, Inc., a Los Angeles-based medical technology company, announced today that it has signed a contract with the University of California, Los Angeles (UCLA) to fund a Phase I pediatric clinical trial to study the use of non-invasive, external Trigeminal Nerve Stimulation (TNS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

24 Oct 2011

Lundbeck's ONFI receives FDA approval for treating seizures associated with Lennox-Gastaut syndrome

Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark, announced today that the U.S. Food and Drug Administration (FDA) has approved ONFI as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients two years and older.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

New neuroconomics study reveals how you make decisions

New research reveals how we make decisions. Birds choosing between berry bushes and investors trading stocks are faced with the same fundamental challenge - making optimal choices in an environment featuring varying costs and benefits.

22 Oct 2011

Neuroscientists discover normal brain communication in people with AgCC

Like a bridge that spans a river to connect two major metropolises, the corpus callosum is the main conduit for information flowing between the left and right hemispheres of our brains. Now, neuroscientists at the California Institute of Technology have found that people who are born without that link-a condition called agenesis of the corpus callosum, or AgCC-still show remarkably normal communication across the gap between the two halves of their brains.

20 Oct 2011

AAN updated guideline on how to best treat essential tremor

The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.

20 Oct 2011